Clinical Trial Update: Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of SyB L-0501RI in combination with Rituximab for lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell Diffuse

Drugs mentioned

• Rituximab (rituximab)
• SyB L-0501RI

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Lymphoma, B-cell, Diffuse | Phase 1, Phase 2 | Status: COMPLETED